Towards an HIV vaccine Selecting promising broadly neutralizing antibodies that can inhibit a range of viral strains

Towards an HIV vaccine Selecting promising broadly neutralizing antibodies that can inhibit a range of viral strains

PROF.DRRAM ,HIV/AIDS,SEX Diseases, Hepatitis .& Deaddiction Expert
profdrram@gmail.com,+917838059592,+919832025033,DELHI,INDIA
HIV/ AIDS,CANCER MODERN MEDICINES AVAILABLE AT CHEAP RATE.
FOLLOW ON FACE BOOK:www.facebook.com/ramkumar
FOLLOW ON TWITTER:www.twitter.com/profdrram

Neutralizing antibodies (Nabs) are immune proteins that recognize, bind to, and trigger the elimination of virus before it can establish a chronic infection. How to elicit a potent Nab response capable of protecting against different HIV subtypes and against different modes of infection is critical to the development of an AIDS vaccine. Two studies published on July 9th in PLOS Pathogens provide results on Nabs that could help guide vaccine design. One shows what type of Nab "repertoire" can be generated following superinfection, and the second one examines the efficacy of Nabs in blocking direct cell-to-cell transmission of HIV.

Julie Overbaugh, from the Fred Hutchinson Cancer Research Center in Seattle, USA, and colleagues characterized the antibodies generated in 21 women who were superinfected, that is, infected sequentially at least twice with HIV by different sexual partners. Their study--the first to examine Nab specificities in a cohort of superinfected individuals, suggests that exposure to diverse HIV subtypes following superinfection may drive a broad and potent Nab response that might be mediated at least in part by polyclonal antibodies targeting multiple different epitopes, or antigenic targets found on the virus.

"As eliciting a highly diverse immune response may be favorable to providing protection against incredibly diverse HIV-1 variants in global circulation," the researchers conclude that their study "supports further investigations of the molecular and functional characteristics of the virus-antibody interplay in superinfected individuals, as superinfection may provide insight to the development of a diverse Nab response with multiple epitope specificities."

Besides infection with free virus, HIV can be transmitted also by direct cell-to-cell contact. And even though the latter is thought to provide a more difficult challenge for neutralizing antibodies, most of the studies so far have examined the antibodies in the context of free virus infections. To be able to address this gap, Alexandra Trkola, from the University of Zurich, Switzerland, and colleagues first developed an assay that can specifically test the ability and potency of Nabs to prevent direct cell transmission of HIV. Proving this point is tricky because free virus infection occurs normally together with cell-to-cell transmission. By establishing an assay system where free virus infection is restricted and infection can only occur through cell-cell transmission, the researchers could then test whether a large selection of Nabs could prevent cell-to-cell transmission of different HIV strains.

Like · Comment · Share